DK2644613T3 - Cellevægspolymerer fra Enterococcus faecalis og anvendelser deraf - Google Patents
Cellevægspolymerer fra Enterococcus faecalis og anvendelser deraf Download PDFInfo
- Publication number
- DK2644613T3 DK2644613T3 DK12162640.2T DK12162640T DK2644613T3 DK 2644613 T3 DK2644613 T3 DK 2644613T3 DK 12162640 T DK12162640 T DK 12162640T DK 2644613 T3 DK2644613 T3 DK 2644613T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell wall
- enterococcal
- antibody
- wall component
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (14)
1. Enterokokcellevægskomponent, der er udvalgt fra gruppen, der består af β-D-GalpNAc-ribitolstrukturer
hvor Ri er udvalgt blandt β-D-Glcp eller α-L-Rhap, og R2 er udvalgt blandt H eller cx-D-Glcp, og farmaceutisk acceptable salte deraf.
2. Antistof, fortrinsvis et monoklonalt antistof eller et antigent fragment deraf, der specifikt genkender en enterokokcellevægskomponent ifølge krav 1.
3. Farmaceutisk præparat, der omfatter mindst én enterokokcellevægskomponent ifølge krav 1 og/eller mindst ét antistof ifølge krav 2 sammen med et farmaceutisk acceptabelt bæremateriale og/eller excipiens.
4. Farmaceutisk præparat ifølge krav 3, hvor præparatet omfatter en cellevægskomponent med formel I.
5. Farmaceutisk præparat ifølge krav 3 eller 4, hvor præparatet er formuleret som en vaccine.
6. Farmaceutisk præparat ifølge et hvilket som helst af kravene 3 til 5, hvor cellevægskomponenten med formel I er til stede i en glycokonjugatvaccine.
7. Fremgangsmåde til fremstilling af enterokokcellevægskomponenten ifølge krav 1, der omfatter isolering af enterokokcellevægskomponenten fra en bakteriefraktion eller omfatter syntetisering af antigenet, i det mindste delvist, ved kemisk syntese.
8. Fremgangsmåde til fremstilling af antistoffet ifølge krav 2, der omfatter immunisering af et pattedyr, fortrinsvis en kanin, med en enterokokcellevægskomponent ifølge krav 1 eller med det farmaceutiske præparat ifølge et hvilket som helst af kravene 3 til 6 og fortrinsvis vaccinen ifølge krav 5 eller 6.
9. Fremgangsmåde til fremstilling af antistoffet ifølge krav 2, der omfatter frembringelse af hybridomaceller, der producerer antistoffet som et monoklonalt antistof, eller omfatter rekombinant fremstilling af antistoffet i en værtscelle.
10. Enterokokcellevægskomponent ifølge krav 1, antistof ifølge krav 2 eller farmaceutisk præparat ifølge et hvilket som helst af kravene 3 til 6 til anvendelse til behandling af sygdomme.
11. Enterokokcellevægskomponent ifølge krav 1, antistof ifølge krav 2 eller farmaceutisk præparat ifølge et hvilket som helst af kravene 3 til 6 til anvendelse til inducering af en immunreaktion mod mindst én enterokokstamme i en vertebrat ved administrering til vertebraten af en immunologisk effektiv mængde af enterokokcellevægskomponenten ifølge krav 1, antistoffet ifølge krav 2 eller det farmaceutiske præparat ifølge et hvilket som helst af kravene 3 til 6.
12. Enterokokcellevægskomponent ifølge krav 1, antistof ifølge krav 2 eller farmaceutisk præparat ifølge et hvilket som helst af kravene 3 til 6 til anvendelse til behandling eller forebyggelse af en bakterieinfektion i en vertebrat ved administrering til vertebraten af en terapeutisk effektiv mængde af enterokokcellevægskomponenten ifølge krav 1, antistoffet ifølge krav 2 eller det farmaceutiske præparat ifølge et hvilket som helst af kravene 3 til 6.
13. Enterokokcellevægskomponent ifølge krav 1, antistof ifølge krav 2 eller farmaceutisk præparat ifølge et hvilket som helst af kravene 3 til 6 til anvendelse ifølge krav 12, hvor bakterieinfektionen er en enterokokinfektion, såsom nosokomial bakteriæmi-infektion, endocarditis, en urinvejsinfektion, operationssårsinfektion og fremmedlegemeinfektion og især er forårsaget af antibiotikumresistente enterokokker.
14. Enterokokcellevægskomponent ifølge krav 1, antistof ifølge krav 2 eller farmaceutisk præparat ifølge et hvilket som helst af kravene 3 til 6 til anvendelse ifølge krav 13, hvor den antibiotikumresistente enterokok er en VRE-stamme, såsom for ekesempel E. faecalis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162640.2A EP2644613B1 (en) | 2012-03-30 | 2012-03-30 | Cell wall polymers of enterococcus faecalis and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2644613T3 true DK2644613T3 (da) | 2015-01-26 |
Family
ID=47843263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12162640.2T DK2644613T3 (da) | 2012-03-30 | 2012-03-30 | Cellevægspolymerer fra Enterococcus faecalis og anvendelser deraf |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9750796B2 (da) |
| EP (1) | EP2644613B1 (da) |
| JP (1) | JP6226948B2 (da) |
| CA (1) | CA2868964A1 (da) |
| DK (1) | DK2644613T3 (da) |
| ES (1) | ES2528344T3 (da) |
| HK (1) | HK1189893A1 (da) |
| PL (1) | PL2644613T3 (da) |
| WO (1) | WO2013143806A1 (da) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012017870A2 (pt) | 2010-01-19 | 2017-09-19 | Univ Freiburg | componentes de parede celular de enterococos e usos dos mesmos |
-
2012
- 2012-03-30 DK DK12162640.2T patent/DK2644613T3/da active
- 2012-03-30 ES ES12162640.2T patent/ES2528344T3/es active Active
- 2012-03-30 PL PL12162640T patent/PL2644613T3/pl unknown
- 2012-03-30 EP EP12162640.2A patent/EP2644613B1/en not_active Not-in-force
-
2013
- 2013-03-04 US US14/387,753 patent/US9750796B2/en active Active
- 2013-03-04 CA CA2868964A patent/CA2868964A1/en not_active Abandoned
- 2013-03-04 JP JP2015502174A patent/JP6226948B2/ja not_active Expired - Fee Related
- 2013-03-04 WO PCT/EP2013/054274 patent/WO2013143806A1/en active Application Filing
-
2014
- 2014-03-26 HK HK14102960.6A patent/HK1189893A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US9750796B2 (en) | 2017-09-05 |
| US20150139998A1 (en) | 2015-05-21 |
| JP2015511610A (ja) | 2015-04-20 |
| CA2868964A1 (en) | 2013-10-03 |
| EP2644613A1 (en) | 2013-10-02 |
| HK1189893A1 (en) | 2014-06-20 |
| WO2013143806A1 (en) | 2013-10-03 |
| PL2644613T3 (pl) | 2015-04-30 |
| ES2528344T3 (es) | 2015-02-09 |
| EP2644613B1 (en) | 2014-10-22 |
| JP6226948B2 (ja) | 2017-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Theilacker et al. | Serodiversity of opsonic antibodies against Enterococcus faecalis—glycans of the cell wall revisited | |
| Geiss-Liebisch et al. | Secondary cell wall polymers of Enterococcus faecalis are critical for resistance to complement activation via mannose-binding lectin | |
| Yang et al. | A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate | |
| Kodali et al. | A vaccine approach for the prevention of infections by multidrug-resistant Enterococcus faecium | |
| JP2014529396A (ja) | パスツレラワクチン | |
| Wenzel et al. | An atypical lipoteichoic acid from Clostridium perfringens elicits a broadly cross-reactive and protective immune response | |
| US11267841B2 (en) | Enterococcus faecalis and/or Enterococcus faecium antigen | |
| US9290531B2 (en) | Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections | |
| AU2010342872B2 (en) | Enterococcal cell wall components and antibacterial use thereof | |
| DK2644613T3 (da) | Cellevægspolymerer fra Enterococcus faecalis og anvendelser deraf | |
| US9255157B2 (en) | Rhamno-polysaccharide from Enterococcus faecium clonal complex 17 and uses thereof | |
| Shashkov et al. | Structure and cross‐reactivity of the O‐specific polysaccharide of Proteus penneri strain 26, another neutral Proteus O‐antigen containing 2‐acetamido‐2, 6‐dideoxy‐l‐glucose (N‐acetyl‐l‐quinovosamine) |